Markets Piper cuts Intersect ENT to neutral; PT to $17 from $30 Piper Jaffray downgraded Intersect ENT (NASDAQ:XENT) to “neutral” from “overweight” and slashed its price target to $17 from $30 after the company reported second quarter results and lowered its revenue guidance to flat... August 2, 2019